Analysis of IL6-protein complexes in chondrosarcoma

Karina Galoian, Shihua Luo, Parthik Patel

Research output: Contribution to journalArticle

Abstract

Cytokines produced in the tumour microenviron-ment serve important roles in cancer pathogenesis or in the supression of disease progression. Metastatic chondrosarcoma is a cancer of the cartilage, and our group previously reported from a human ELISA assay that interleukin 6 (IL6) expression in JJ012 chondrosarcoma cells was 86-fold lower than that in C28 chondrocytes, indicating its role as an anti-inflammatory and anti-tumorigenic factor. Additionally, to the best of our knowledge, the study was the first to demonstrate downregulation of IL6 in a human chondrosarcoma cell line. To fully elucidate the effect of this IL6 downregulation, it is important to identify protein complexes and components that bind IL6 and potentially affect its gene expression directly or indirectly. To investigate IL6-protein interactions leading to these differences in IL6 expression, the current study performed a gel retardation electrophoretic mobility shift assay (EMSA), followed by 2D gel phoresis, in-gel trypsin digestion and proteomic mass spectral analysis. The results indicated a presence of ubiquitination enzymes in C28 chondrocytes, while none were identified in JJ012 chondrosarcoma cells. While it seems counterintuitive, it may be that the absence of ubiquitination of certain factors leads to the downregulation of IL6 expression in human chondrosarcoma. Therefore, dysregulated ubiquitination may be among the possible mechanisms for the markedly reduced IL6 expression in chondrosarcoma.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalBiomedical Reports
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Chondrosarcoma
Interleukin-6
Ubiquitination
Proteins
Down-Regulation
Gels
Chondrocytes
Assays
Neoplasms
Electrophoretic mobility
Cartilage
Electrophoretic Mobility Shift Assay
Gene expression
Proteomics
Spectrum analysis
Trypsin
Disease Progression
Tumors
Digestion
Anti-Inflammatory Agents

Keywords

  • Chondrocytes
  • Chondrosarcoma
  • Cytokines
  • Interleukin 6
  • Mass spectrometry
  • Ubiquitination

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Analysis of IL6-protein complexes in chondrosarcoma. / Galoian, Karina; Luo, Shihua; Patel, Parthik.

In: Biomedical Reports, Vol. 8, No. 1, 01.01.2018, p. 91-98.

Research output: Contribution to journalArticle

Galoian, Karina ; Luo, Shihua ; Patel, Parthik. / Analysis of IL6-protein complexes in chondrosarcoma. In: Biomedical Reports. 2018 ; Vol. 8, No. 1. pp. 91-98.
@article{ac3819cea1f44d25bb81a0b9267a1960,
title = "Analysis of IL6-protein complexes in chondrosarcoma",
abstract = "Cytokines produced in the tumour microenviron-ment serve important roles in cancer pathogenesis or in the supression of disease progression. Metastatic chondrosarcoma is a cancer of the cartilage, and our group previously reported from a human ELISA assay that interleukin 6 (IL6) expression in JJ012 chondrosarcoma cells was 86-fold lower than that in C28 chondrocytes, indicating its role as an anti-inflammatory and anti-tumorigenic factor. Additionally, to the best of our knowledge, the study was the first to demonstrate downregulation of IL6 in a human chondrosarcoma cell line. To fully elucidate the effect of this IL6 downregulation, it is important to identify protein complexes and components that bind IL6 and potentially affect its gene expression directly or indirectly. To investigate IL6-protein interactions leading to these differences in IL6 expression, the current study performed a gel retardation electrophoretic mobility shift assay (EMSA), followed by 2D gel phoresis, in-gel trypsin digestion and proteomic mass spectral analysis. The results indicated a presence of ubiquitination enzymes in C28 chondrocytes, while none were identified in JJ012 chondrosarcoma cells. While it seems counterintuitive, it may be that the absence of ubiquitination of certain factors leads to the downregulation of IL6 expression in human chondrosarcoma. Therefore, dysregulated ubiquitination may be among the possible mechanisms for the markedly reduced IL6 expression in chondrosarcoma.",
keywords = "Chondrocytes, Chondrosarcoma, Cytokines, Interleukin 6, Mass spectrometry, Ubiquitination",
author = "Karina Galoian and Shihua Luo and Parthik Patel",
year = "2018",
month = "1",
day = "1",
doi = "10.3892/br.2017.1016",
language = "English (US)",
volume = "8",
pages = "91--98",
journal = "Biomedical Reports",
issn = "2049-9434",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Analysis of IL6-protein complexes in chondrosarcoma

AU - Galoian, Karina

AU - Luo, Shihua

AU - Patel, Parthik

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cytokines produced in the tumour microenviron-ment serve important roles in cancer pathogenesis or in the supression of disease progression. Metastatic chondrosarcoma is a cancer of the cartilage, and our group previously reported from a human ELISA assay that interleukin 6 (IL6) expression in JJ012 chondrosarcoma cells was 86-fold lower than that in C28 chondrocytes, indicating its role as an anti-inflammatory and anti-tumorigenic factor. Additionally, to the best of our knowledge, the study was the first to demonstrate downregulation of IL6 in a human chondrosarcoma cell line. To fully elucidate the effect of this IL6 downregulation, it is important to identify protein complexes and components that bind IL6 and potentially affect its gene expression directly or indirectly. To investigate IL6-protein interactions leading to these differences in IL6 expression, the current study performed a gel retardation electrophoretic mobility shift assay (EMSA), followed by 2D gel phoresis, in-gel trypsin digestion and proteomic mass spectral analysis. The results indicated a presence of ubiquitination enzymes in C28 chondrocytes, while none were identified in JJ012 chondrosarcoma cells. While it seems counterintuitive, it may be that the absence of ubiquitination of certain factors leads to the downregulation of IL6 expression in human chondrosarcoma. Therefore, dysregulated ubiquitination may be among the possible mechanisms for the markedly reduced IL6 expression in chondrosarcoma.

AB - Cytokines produced in the tumour microenviron-ment serve important roles in cancer pathogenesis or in the supression of disease progression. Metastatic chondrosarcoma is a cancer of the cartilage, and our group previously reported from a human ELISA assay that interleukin 6 (IL6) expression in JJ012 chondrosarcoma cells was 86-fold lower than that in C28 chondrocytes, indicating its role as an anti-inflammatory and anti-tumorigenic factor. Additionally, to the best of our knowledge, the study was the first to demonstrate downregulation of IL6 in a human chondrosarcoma cell line. To fully elucidate the effect of this IL6 downregulation, it is important to identify protein complexes and components that bind IL6 and potentially affect its gene expression directly or indirectly. To investigate IL6-protein interactions leading to these differences in IL6 expression, the current study performed a gel retardation electrophoretic mobility shift assay (EMSA), followed by 2D gel phoresis, in-gel trypsin digestion and proteomic mass spectral analysis. The results indicated a presence of ubiquitination enzymes in C28 chondrocytes, while none were identified in JJ012 chondrosarcoma cells. While it seems counterintuitive, it may be that the absence of ubiquitination of certain factors leads to the downregulation of IL6 expression in human chondrosarcoma. Therefore, dysregulated ubiquitination may be among the possible mechanisms for the markedly reduced IL6 expression in chondrosarcoma.

KW - Chondrocytes

KW - Chondrosarcoma

KW - Cytokines

KW - Interleukin 6

KW - Mass spectrometry

KW - Ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=85048459649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048459649&partnerID=8YFLogxK

U2 - 10.3892/br.2017.1016

DO - 10.3892/br.2017.1016

M3 - Article

AN - SCOPUS:85048459649

VL - 8

SP - 91

EP - 98

JO - Biomedical Reports

JF - Biomedical Reports

SN - 2049-9434

IS - 1

ER -